1.1 billion antidepressants have been reviewed in China and the West

Medicine Network November 25th, November 23rd, the official website of the State Drug Administration shows that the hydrochloric acid lositin intestinal capsules of Chinese and Western medicine on the drug through a consistent evaluation of supplementary applications.
2019, China's public medical terminals have sales of more than 1.1 billion yuan, according to the Company's 100 million-meter intranet data.
chinese medicine for the third evaluation of the variety of enterprises.
is a selective 5-hydroxysamine (5-HT) and epinephrine (NE) reuptake inhibitor developed by Lilly and is clinically used primarily to treat depression.
depression is a common mental illness, with 350 million people suffering from depression worldwide, of whom more than 180 million are now suffering from various types of mental illness in China, making it a common disease that endangers people's health.
recent years, dolositin in the domestic market size continued to expand. according to
meters of intranet data, in 2019 China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) terminal Sales of more than 1.1 billion yuan;
China's public medical institutions terminal degree loxitin sales (unit: 10,000 yuan) Source: Minet China's public medical institutions terminal competition pattern is currently listed in China' degree loxitin products have hydrochloric acid loxitin intestinal capsules, hydrochloric acid loxitin intestinal solution tablets, hydrochloric acid Loxitin intestinal capsule manufacturers have Lilly and Chinese medicine Chinese western medicine, Pelte pharmaceutical industry, stone medicine Ouyi and other 4, hydrochloric acid loxitin intestinal solution tablets manufacturers only chinese medicine Chinese western medicine and Enhua pharmaceutical industry.
degrees of Lausitin evaluation source: Mi-Net consistency evaluation database Mi-Net data show that hydrochloric loxitin intestinal solution has not yet been adopted by enterprises through the consistent evaluation.
hydrochloric acid Lositin intestinal capsule evaluation enterprises gathered 3, respectively, Pelte Pharmaceuticals, Stone Pharmaceuticals Europe, Chinese and Western Pharmaceuticals.
source: MiNet Database, NMPA